Clinical trials: Psychological Disorder
Primary Progressive Aphasia, Behavioral Variant of Frontotemporal Dementia
Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia
This study is designed to learn more about overall tau burden in the brain of patients with Primary Progressive Aphasia (PPA) and Frontotemporal Dementia.
- Conditions
- Primary Progressive Aphasia, Behavioral Variant of Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant
- Trial name
- SLD3 (NCT02736695)
- Testing
- F-18 AV 1451
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Mayo Clinic
Major Depressive Disorder
A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder
The purpose of this study is to evaluate the long-term safety and tolerability of vilazodone for the treatment of MDD in pediatric outpatients (7-17 years).
- Trial name
- VLZ-MD-23 (NCT02436239)
- Testing
- Vilazodone
- Where
- 56 sites in United States, Canada
- Volunteers
- 330 people
- Sponsor
- Forest Laboratories
Nicotine Use Disorder
Effects of E-cigarette Flavors on Youth TCORS 2.0
This study is an examination of the influence of sweet and cooling flavors on the appeal and abuse potential of nicotine-containing e-cigarettes among susceptible youth.
- Trial name
- NCT03634839
- Testing
- Flavoring Agents, Nicotine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Yale University
PostTraumatic Stress Disorder
Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Effectiveness
This is a multisite, randomized, blinded, sham-procedure-controlled study to evaluate the efficacy of right-sided stellate ganglion block (SGB) on the acute symptomatology of Post traumatic Stress Disorder (PTSD), evaluated by…
- Trial name
- NCT03077919
- Testing
- Ropivacaine
- Where
- 3 sites in United States, Germany
- Volunteers
- 113 people
- Sponsor
- RTI International
Nicotine Dependence
Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention
The purpose of this research study is to find out if an investigational drug, GSK598809 can help people who have very recently quit smoking; the investigators want to find out if continuing to take GSK598809 over six weeks can…
- Trial name
- NCT01188967
- Testing
- GSK598809
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Massachusetts General Hospital
Alzheimer's Disease
A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group study using a Bayesian design with response adaptive randomization across placebo or 5 active arms of lecanemab to determine clinical efficacy…
- Trial name
- NCT01767311
- Testing
- Lecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg
- Where
- 169 sites in United States, Canada and 9 more
- Volunteers
- 856 people
- Sponsor
- Eisai Inc.
Schizophrenia
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics.
- Trial name
- NCT00149734
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Attention Deficit and Disruptive Behavior Disorders, Attention Deficit Disorder With Hyperactivity
Effectiveness of the Quotient® ADHD Assessment in a System of Care
The study goal is to examine whether the use of an objective computerized neuroassessment (the Quotient System) for Attention-Deficit/Hyperactivity Disorder (ADHD) is related to improved outcomes among pediatric patients being…
- Trial name
- NCT02094612
- Testing
- Quotient®, Usual Clinic ADHD Care
- Where
- 3 sites in United States
- Volunteers
- 207 people
- Sponsor
- Kaiser Permanente
Schizophrenia
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning.
- Trial name
- NCT04846881
- Testing
- Iclepertin
- Where
- 127 sites in United States, Argentina and 16 more
- Volunteers
- 611 people
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort.
- Trial name
- NCT04437511
- Testing
- Donanemab
- Where
- 274 sites in United States, Australia and 7 more
- Volunteers
- 1,736 people
- Sponsor
- Eli Lilly and Company
Cognitive Dysfunction
Probing Cortical Excitability and Cognitive Function With TMS
The overarching purpose of this study is to develop a technique that is capable of identifying neurophysiological biomarkers sensitive enough to detect preclinical dementia by integrating Transcranial Magnetic Stimulation (TMS)…
- Trial name
- NCT03652012
- Testing
- Transcranial Magnetic Stimulation (TMS)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Heroin Addiction
Buprenorphine for Prisoners
This five-year study examines the effectiveness of buprenorphine treatment provided to previously-addicted inmates(N=320; 160 males, 160 females) initiated in prison and continued in the community.
- Trial name
- NCT00574067
- Testing
- Buprenorphine +OTP, Buprenorphine +CHC, Counseling +OTP
- Where
- 2 sites in United States
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Friends Research Institute, Inc.
Aphasia, Apraxia of Speech
Treatments of Acquired Apraxia of Speech
This study was designed to examine the effects of speech therapy on ability to produce speech sounds in persons with acquired apraxia of speech.
- Conditions
- Aphasia, Apraxia of Speech, Stroke
- Trial name
- Apraxia (NCT01483807)
- Testing
- Sound Production Treatment - Blocked, Sound Production Treatment - Random
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- VA Office of Research and Development
Smoking Cessation
Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening
To compare the effectiveness of four interventions to promote sustained, biochemically confirmed smoking abstinence for 6 months among underserved smokers referred for lung cancer screening at four large U.S. health systems.
- Trial name
- NCT04798664
- Testing
- Removal of Financial Barriers, Financial Incentives, Mobile Health Application
- Where
- 5 sites in United States
- Volunteers
- 3,228 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Posttraumatic Stress Disorder
MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD
The goal of this clinical trial is to learn if cognitive-behavioral conjoint therapy (CBCT) in combination with MDMA-assisted therapy is safe and effective in people with chronic PTSD and their partners.
- Trial name
- NCT02876172
- Testing
- MDMA, CBCT, Therapy
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Resilient Pharmaceuticals
Alcoholism, Substance-related Disorders
Treatment Engagement With Technology-assisted Treatment
This research is being done to study whether using an Internet-based program, called the Therapeutic Education System (TES), would be helpful for the treatment of substance use and other psychiatric problems.
- Conditions
- Alcoholism, Substance-related Disorders, Mentally Ill Chemical Abuse, Educational Technology
- Trial name
- TETAT (NCT02674477)
- Testing
- Therapeutic Education System (TES), Treatment as Usual (TAU)
- Volunteers
- 95 people
- Sponsor
- Johns Hopkins University
Autism Spectrum Disorder, Anxiety
Specifying and Treating Anxiety in Autism Research
In the Specifying and Treating the Anxiety Phenotype in Autism Spectrum Disorder (STAAR) study, we conducted a16-week randomized comparative treatment trial of the Behavioral Intervention for Anxiety in Children with Autism…
- Trial name
- STAAR (NCT03279471)
- Testing
- Sertraline, CBT/BIACA
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of California, Davis
Depressive Disorder, Major
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
The purpose of the study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder…
- Trial name
- Aspire I (NCT03039192)
- Testing
- Esketamine, Standard of Care
- Where
- 56 sites in United States, Bulgaria and 9 more
- Volunteers
- 226 people
- Sponsor
- Janssen Research & Development, LLC
Parkinson's Disease, Mild Cognitive Impairment
Mild Cognitive Impairment in Parkinson's Disease
Mild cognitive impairment, including difficulty with solving problems, planning, attention, or recalling information, can be a significant problem for individuals with Parkinson's disease.
- Trial name
- NCT01519271
- Testing
- Exelon Patch (rivastigmine transdermal system)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Pennsylvania
Posttraumatic Stress Disorders
Eszopiclone for the Treatment of Posttraumatic Stress Disorder
The purpose of this study is to determine if eszopiclone relative to placebo (sugar pill) is effective and tolerable for people with posttraumatic stress disorder (PTSD)-related sleep disturbance.
- Trial name
- NCT01605253
- Testing
- Eszopiclone
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Rush University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.